

*The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **MINGYUAN MEDICARE DEVELOPMENT COMPANY LIMITED**

**銘源醫療發展有限公司\***

*(incorporated in Bermuda with limited liability)*

**(Stock Code: 0233)**

This announcement is made by the Company pursuant to Rule 13.09(1) of the Listing Rules.

The Board is pleased to announce that Healthdigit, a wholly owned subsidiary of the Company, has completed the development of the TB Chip for diagnosis of TB. The application process to SFDA for the granting of drug license is underway with final approval expected in 2009.

This announcement is made by Mingyuan Medicare Development Company Limited (the “Company”) pursuant to Rule 13.09(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”).

The Board of Directors (the “Board”) of the Company is pleased to announce that SHMY Healthdigit Biochips Company Limited (“Healthdigit”), a wholly owned subsidiary of the Company, has completed the development of a protein chip product (the “TB Chip”) for the rapid diagnosis of tuberculosis (“TB”), one of the most infectious diseases worldwide. The TB Chip is able to detect multiple TB specific antibodies in the blood serum of the patient without special laboratory settings rapidly and efficiently, and is capable of conducting TB screening for the mass population. The Board believes that this kind of rapid test could contribute more positively towards a better management of tuberculosis. The application process to State Food and Drug Administration (“SFDA”) for the granting of drug license is underway with final approval expected in 2009.

The TB Chip is the first product completed by Healthdigit with the technology developed at the Tuberculosis Research Laboratory of Second Affiliated Hospital of the PLA General Hospital in Beijing (the “Hospital”). In August 2007, Healthdigit signed a long-term strategic partnership agreement with the Hospital for the collaboration in scientific research and commercialization of technologies developed by the Hospital.

As at the date of this announcement, the executive directors of the Company are Mr. Yao Yuan (Chairman), Mr. Chien Hoe Yong, Henry (CEO), Mr. Iu Chung, Mr. Hu Jun, and Mr. Yu Tin Jun; the independent non-executive directors are Dr. Lam Lee G., Mr. Hu Jin Hua and Mr. Lee Sze Ho, Henry.

On behalf of the Board  
**Chien Hoe Yong, Henry**  
*CEO and Executive Director*

Hong Kong, 15 May 2008

\* *For identification purposes only*